The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression
about
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionSelective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusionEvolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.Clinical significance of HIV-1 coreceptor usage.A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityReconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence DataAppreciating HIV type 1 diversity: subtype differences in Env.Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C. trachomatis infection.R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expressionFrequent detection of CXCR4-using viruses among Brazilian blood donors with HIV-1 long-standing infection and unknown clinical stage: Analysis of massive parallel sequencing dataAn evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Serial evolutionary networks of within-patient HIV-1 sequences reveal patterns of evolution of X4 strains.Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmissionHigh Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsThe role of chemokine receptors in HIV infection.Viral genetic evolution in macaques infected with molecularly cloned simian immunodeficiency virus correlates with the extent of persistent viremia.Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.Frequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West AfricaPolymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infectionInduction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.Antiretroviral therapy in the clinicCoreceptor and cytokine concentrations may not explain differences in disease progression observed in HIV-1 clade A and D infected Ugandans.Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist.Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infectionPositive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesisDistinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsInhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.Coreceptor usage, diversity, and divergence in drug-naive and drug-exposed individuals from Malawi, infected with HIV-1 subtype C for more than 20 years.Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.
P2860
Q24538985-3CEE3347-1449-4D02-BEF4-67B3871DDD1AQ24673389-0C34642B-DA16-463F-AC90-8FE3B39E35AFQ24678540-E9F44199-0A15-4B54-809C-DDB28C3F68C6Q24815687-BDC3FAAA-F5C6-439C-868C-A84386AEE61AQ27691426-0A0DFDF0-7011-48A5-9667-50C0DDAE11E9Q28343321-B831513E-E988-410D-A4E9-EB650ED99C06Q29394572-E52195F0-2B99-465E-B438-5429B0DCE6E3Q30375834-DF8B895D-3F6F-4A9C-B018-A758B292C217Q30413754-62FEA0E2-3BBA-47BE-B15C-8F344FD86771Q30448634-E523E663-7B46-4E64-A0F6-25C30064BB43Q31044033-B357DDAE-1C05-455A-8A41-EF1F71BF7ACFQ33307183-8755EE6F-D4E3-45B3-87C8-ACAFBC1EDB13Q33455862-21A94197-8F80-41BF-8A29-EA70240E110DQ33468625-EFD44792-919A-444D-84D7-162389F4B3A3Q33565651-3C3FFAE2-F4C9-434C-98BD-880A56557D60Q33582135-F2CE6BB1-8245-4346-900E-D3D0E699DFB8Q33639712-63BAB4B6-D066-4D4E-9DAC-F507ADD6F615Q33645828-A40E678C-698C-44A9-9398-C9D02E96889DQ33650466-2AA3457D-1C94-43D3-8620-7F5652235030Q33685141-DDC6514D-6E32-4739-BC5D-90ED5C9640C1Q33711682-19DD5BCF-9C14-4EC0-B93D-13B387A9384EQ33783429-96C9DE0E-6B4D-4E6F-8952-6624EC5AC9D8Q33784708-943953A0-2CB2-4123-B7D9-6C50EC7A7105Q33793066-2475B70F-3311-4CA6-A51E-CC042C1FFDC1Q33805434-C4AC440F-392E-41B3-81F1-BF406D458DCDQ33807529-7E219931-4459-49DB-B5E3-26C77C72F4DEQ33823310-70A616D2-A46B-425F-B525-D1DE6A618371Q33825654-63E7994B-5D90-433C-BA74-6E9A4553D1BCQ33842286-240398F2-C64D-474C-9B18-B252EB9D7AA1Q33877347-E911C249-C5BA-456E-B5C4-0A278CDEADD4Q33927434-7871677A-E845-4B84-ADEC-B3AA334F7C81Q33938250-896F97DE-A55C-4F80-A4E3-F82661349066Q33951977-58B26A95-298C-43CA-8127-09867203D336Q33997410-1FF25656-3C99-4364-8366-7BD32E1E873CQ34010283-CC5584E3-D3F4-4065-8D20-2F4AB3AFCE12Q34055508-7AAE5A7D-6697-41C3-8F5C-CC7FC096BDB0Q34057868-D4DDE832-CA78-4588-A883-EADE2CB6DFBEQ34169244-F4D79096-99C9-4CCD-AE10-6EBCB111FDABQ34269253-D84E60B6-2073-4A81-9130-12DFDDE0C872Q34341001-E479764D-E615-4E57-921A-869C82F7F6EE
P2860
The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression
description
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1994
@ast
im Mai 1994 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1994/05/01)
@sk
vědecký článek publikovaný v roce 1994
@cs
wetenschappelijk artikel (gepubliceerd op 1994/05/01)
@nl
наукова стаття, опублікована в травні 1994
@uk
مقالة علمية (نشرت في مايو 1994)
@ar
name
The impact of the syncytium-in ...... y virus on disease progression
@ast
The impact of the syncytium-in ...... y virus on disease progression
@en
The impact of the syncytium-in ...... y virus on disease progression
@nl
type
label
The impact of the syncytium-in ...... y virus on disease progression
@ast
The impact of the syncytium-in ...... y virus on disease progression
@en
The impact of the syncytium-in ...... y virus on disease progression
@nl
prefLabel
The impact of the syncytium-in ...... y virus on disease progression
@ast
The impact of the syncytium-in ...... y virus on disease progression
@en
The impact of the syncytium-in ...... y virus on disease progression
@nl
P3181
P356
P1476
The impact of the syncytium-in ...... y virus on disease progression
@en
P2093
D. D. Richman
S. A. Bozzette
P304
P3181
P356
10.1093/INFDIS/169.5.968
P407
P577
1994-05-01T00:00:00Z